TradingKey

关于 Pacira Biosciences Inc 公司

Pacira BioSciences, Inc. 是 Pacira Pharmaceuticals, Inc. 的控股公司。该公司的非阿片类治疗药物包括 EXPAREL（布比卡因脂质体注射混悬液），这是一种用于术后疼痛管理的长效局部镇痛药；ZILRETTA（曲安奈德缓释注射混悬液），这是一种缓释关节内 (IA) 皮质类固醇注射剂，用于治疗 OA 膝关节疼痛；以及 Iovera，这是一种新型手持设备，可通过精确控制的低温剂量向目标神经提供即时、长效、无药物的疼痛控制。EXPAREL 用于多种骨科手术，包括关节重建、肩部、脊柱、四肢手术和髋部骨折。该公司正在开发干预措施来治疗涉及交感神经系统的衰弱性疾病，例如心脏电风暴、慢性疼痛。其临床开发项目包括 PCRX-201 和基于 pMVL 的临床项目。

公司简介

公司代码PCRX

公司名称Pacira Biosciences Inc

上市日期Feb 03, 2011

CEOMr. Frank D. Lee

员工数量790

证券类型Ordinary Share

年结日Feb 03

公司地址2000 Sierra Point Parkway

城市BRISBANE

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编94005

电话16502428052

网址https://www.pacira.com/

公司代码PCRX

上市日期Feb 03, 2011

CEOMr. Frank D. Lee

公司高管

名称

名称/职务

职务

持股

持股变动

Dr. Mark A. Kronenfeld, M.D.

Independent Director

34.90K

+40.15%

Dr. Jonathan Slonin, M.D.

Chief Medical Officer

34.69K

-12.78%

Mr. Daryl Gaugler

Executive Vice President - Commercial Operations

32.29K

-51.29%

Ms. Laura A. Brege

Independent Chairman of the Board

23.71K

+35.11%

Mr. Abraham N. (Abe) Ceesay

Independent Director

11.39K

+117.84%

Ms. Lauren Riker

Senior Vice President - Finance, Principal Accounting Officer

5.98K

-59.94%

Mr. Michael J. Yang

Independent Director

--

Mr. Shawn M. Cross

Chief Financial Officer

--

Dr. Marcelo Bigal, M.D., Ph.D.

Independent Director

--

Ms. Susan Mesco

Investor Relations

--

名称

名称/职务

职务

持股

持股变动

Dr. Mark A. Kronenfeld, M.D.

Independent Director

34.90K

+40.15%

Dr. Jonathan Slonin, M.D.

Chief Medical Officer

34.69K

-12.78%

Mr. Daryl Gaugler

Executive Vice President - Commercial Operations

32.29K

-51.29%

Ms. Laura A. Brege

Independent Chairman of the Board

23.71K

+35.11%

Mr. Abraham N. (Abe) Ceesay

Independent Director

11.39K

+117.84%

Ms. Lauren Riker

Senior Vice President - Finance, Principal Accounting Officer

5.98K

-59.94%

收入明细

FY2025Q1

FY2024

FY2023

FY2022

FY2021

FY2020

业务USD

名称

营收

占比

EXPAREL

136.53M

0.00%

ZILRETTA

23.34M

0.00%

iovera

5.12M

0.00%

Bupivacaine liposome injectable suspension

2.60M

0.00%

暂无数据

业务

地区

业务USD

名称

营收

占比

EXPAREL

136.53M

0.00%

ZILRETTA

23.34M

0.00%

iovera

5.12M

0.00%

Bupivacaine liposome injectable suspension

2.60M

0.00%

股东统计

更新时间: 7月13日周日

持股股东

股东类型

持股股东

占比

BlackRock Institutional Trust Company, N.A.

14.61%

The Vanguard Group, Inc.

11.21%

D. E. Shaw & Co., L.P.

4.89%

Renaissance Technologies LLC

4.84%

Dimensional Fund Advisors, L.P.

4.43%

Other

60.03%

持股股东

占比

BlackRock Institutional Trust Company, N.A.

14.61%

The Vanguard Group, Inc.

11.21%

D. E. Shaw & Co., L.P.

4.89%

Renaissance Technologies LLC

4.84%

Dimensional Fund Advisors, L.P.

4.43%

Other

60.03%

股东类型

持股股东

占比

Investment Advisor

49.40%

Hedge Fund

27.65%

Investment Advisor/Hedge Fund

25.71%

Research Firm

5.57%

Pension Fund

1.69%

Individual Investor

1.48%

Bank and Trust

1.05%

Sovereign Wealth Fund

0.32%

Holding Company

0.31%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

611

52.44M

113.25%

-16.62M

2025Q1

638

53.73M

116.03%

-16.46M

2024Q4

638

52.13M

112.66%

-21.91M

2024Q3

638

53.62M

116.22%

-11.06M

2024Q2

624

54.29M

116.65%

-6.10M

2024Q1

627

51.47M

110.71%

-7.99M

2023Q4

621

50.55M

108.88%

-6.71M

2023Q3

612

49.73M

107.18%

-6.05M

2023Q2

605

49.27M

107.14%

-5.45M

2023Q1

601

48.56M

105.72%

-5.54M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

BlackRock Institutional Trust Company, N.A.

6.77M

14.61%

-179.41K

-2.58%

Mar 31, 2025

The Vanguard Group, Inc.

5.19M

11.21%

-25.27K

-0.48%

Mar 31, 2025

D. E. Shaw & Co., L.P.

2.26M

4.89%

+6.43K

+0.29%

Mar 31, 2025

Renaissance Technologies LLC

2.24M

4.84%

+248.00K

+12.45%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

2.05M

4.43%

+217.22K

+11.86%

Mar 31, 2025

State Street Global Advisors (US)

1.98M

4.27%

+13.89K

+0.71%

Mar 31, 2025

DOMA Perpetual Capital Management, LLC

1.80M

3.9%

+56.22K

+3.22%

Mar 31, 2025

Balyasny Asset Management LP

1.57M

3.38%

+1.13M

+260.53%

Mar 31, 2025

Citadel Advisors LLC

1.33M

2.87%

+1.28M

+2700.84%

Mar 31, 2025

Alyeska Investment Group, L.P.

1.31M

2.83%

+1.31M

--

Mar 31, 2025

持股ETF

更新时间: 8月2日周六

机构名称

占比

Pacer US Small Cap Cash Cows Growth Leaders ETF

2.97%

SPDR S&P Pharmaceuticals ETF

2.6%

Invesco Pharmaceuticals ETF

2.5%

Simplify Health Care ETF

2.21%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.85%

Invesco S&P SmallCap Health Care ETF

0.79%

VictoryShares Small Cap Free Cash Flow ETF

0.76%

iShares U.S. Pharmaceuticals ETF

0.56%

Royce Quant Small-Cap Quality Value ETF

0.53%

Distillate Small/Mid Cash Flow ETF

0.45%

Pacer US Small Cap Cash Cows Growth Leaders ETF

占比2.97%

SPDR S&P Pharmaceuticals ETF

占比2.6%

Invesco Pharmaceuticals ETF

占比2.5%

Simplify Health Care ETF

占比2.21%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比1.85%

Invesco S&P SmallCap Health Care ETF

占比0.79%

VictoryShares Small Cap Free Cash Flow ETF

占比0.76%

iShares U.S. Pharmaceuticals ETF

占比0.56%

Royce Quant Small-Cap Quality Value ETF

占比0.53%

Distillate Small/Mid Cash Flow ETF

占比0.45%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Pacira Biosciences Inc

22.547USD

Pacira Biosciences Inc

22.547

概览

公司

财务